Solve the Translational Gap, from Deeper Resolution of Fibrosis Pathology to Clinically Dynamic & Predictive Biomarker Rationale

October 24-26 | Boston

Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit!

Welcome to the 7th Antifibrotic Drug Development (AFDD) Summit

Solve the Translational Gap, from Deeper Resolution of Fibrosis Pathology to Clinically Dynamic & Predictive Biomarker Rationale

As fibrosis stakeholders invest in bolstering their early pipeline to limit early candidate drop off, the 2023 7th Antifibrotic Drug Development (AFDD) Summit explored actionable strategies to take this further.

The AFDD event provided you with skills needed to better interrogate antifibrotic potential and bridge the translational gap:

Pioneering fibrosis quantification with more sensitive fluid and imaging biomarkers that predict, stage and diagnose fibrosis
More confident translation to the clinic by harnessing state-of-the-art in-vitro models that truly recapitulate fibrosis
Game-changing target ID supercharged by uncovering molecular networks, novel pathways and mapping crosstalk

With 80+ experts from early-stage research to late translational, this unique scientific forum united industry leaders across fibrotic disease to energize your fibrosis research.

Previously Attending Companies Include:

2560px-Boehringer_Ingelheim_Logo.svg
Genentech_Logo
Pfizer_(2021)
Gilead_Logo
morphic-brand-notmlogo-rgb-082321-01

'Excellent speakers. The networking events were well knitted into the entire day of the conference’ 

ARIA Pharmaceuticals, Senior Vice President - Non-Clinical Research, Development & Chemistry

 

'Excellent quality of the program -  I learned a lot!'

University of Strasbourg, Institute Head, Founder, Professor of Medicine

'The quality of the speakers and of the talks was outstanding. Additionally, the questions were thoughtful and high yield’ 

Novartis, Executive Director, Discovery Respiratory Lead

'Good scientific presentations and discussion

Genentech Vice President and Therapeutic Area Head, Immunology and Regenerative Medicine

'Academic - pharmaceutical company interactions provide the greatest hope for achieving therapeutic success in fibrotic disease'

University of Pittsburgh, Professor of Medicine

Our 2023 Partners:

Expertise Partners:

Nordic-Bioscience
fibrofind

Innovation Partner:

logo

Exhibition Partner:

Aragen_Logo
download